A preclinical study found that antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF)-dependent signaling pathway promoted alleviation of hypoxia, efficient tumor infiltration by CD8-positive T cells, and reduced recruitment of tumor-associated macrophages.10, 11, 12, 13, 14 Therefore, the addition of an antiangiogenic drug to ICI may enhance antitumor immune responses by normalizing the tumor microenvironment. The gene discussed is VEGFA; the disease is neoplasm.